Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17447460 | 0.84 | POLB (0.82) | POLBHCAR2USP2NPC1RAB9A | |
| SCHEMBL9819478 | 0.84 | FABP4 (0.54) | POLBLMNAFABP4HTTALDH1A1 | |
| SCHEMBL9819468 | 0.84 | LMNA (0.47) | POLBLMNAFABP4HTTALDH1A1 | |
| SCHEMBL9819538 | 0.83 | POLB (0.47) | POLBNPC1RAB9ALMNAFABP4 | |
| SCHEMBL9819406 | 0.82 | LMNA (0.46) | POLBLMNAFABP4HTTALDH1A1 | |
| SCHEMBL18896240 | 0.82 | POLB (0.77) | POLBHCAR2USP2NPC1RAB9A | |
| SCHEMBL20152042 | 0.82 | POLB (0.77) | POLBHCAR2USP2NPC1RAB9A | |
| SCHEMBL9819541 | 0.81 | PPARA (0.54) | POLBNPC1RAB9ALMNAFABP4 | |
| SCHEMBL19169696 | 0.81 | POLB (0.66) | POLBHCAR2USP2NPC1RAB9A | |
| SCHEMBL9819516 | 0.79 | LMNA (0.44) | POLBLMNAFABP4KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-1817029-B1 | ISOXAZOLIC DERIVATIVE TO RELIEVE NEUROPATHIC PAIN | ZAMBON SPA (IT) | 2009-09-16 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080108679-A1 | Isoxazolic Derivative to Relieve Neuropathic Pain | ZAMBON S.P.A. (IT) | 2008-05-08 | — | — | US | disclosed |
| US-20080108679-A1 | Isoxazolic Derivative to Relieve Neuropathic Pain | ZAMBON S.P.A. (IT) | 2008-05-08 | — | — | US | disclosed |
| EP-0317588-B1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 1991-08-07 | — | — | EP | disclosed |
| US-4985428-A | Isoxazoles with nootropic activity | ZAMBON GROUP S.P.A. (IT) | 1991-01-15 | — | — | US | disclosed |
| EP-0317588-A1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY. | ZAMBON SPA (IT) | 1989-05-31 | — | — | EP | disclosed |
| WO-1988009330-A1 | ISOXAZOLES WITH NOOTROPIC ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 1988-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | POLB 2718/4885HCAR2 2135/4885USP2 2436/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | POLB 1573/4885HCAR2 446/4885USP2 4124/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | POLB 3970/4885HCAR2 183/4885USP2 3233/4885 |
| US-20080108679-A1 | Isoxazolic Derivative to Relieve Neuropathic Pain | INA, P2RX5, P2RX3 | POLB 4426/4885HCAR2 418/4885USP2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.